AustinPx, a contract development and manufacturing organisation (CDMO) specialising in analytical and formulation development services and cGMP manufacturing for small molecule drugs, has announced the expansion of its capabilities to meet industry demand for the company’s services and expertise.
The company has added new spray drying and encapsulation capabilities and has also expanded its GMP manufacturing capacity for high shear and fluid bed granulation.
AustinPx has installed and validated a Dott. Bonapace INCAP capsule filler, a Freund-Vector VFC3 model fluid bed, and a Freund-Vector GMXB-Pilot model granulator. The INCAP rounds out the company’s solid dose manufacturing capabilities, while the fluid bed and granulator supplement the company’s manufacturing scale.
The investments are a key component of AustinPx’s larger strategy to expand our oral dose development and manufacturing capabilities to better serve our clients’ increasing demand
- Justin Keen, PhD, Senior VP of Operations
Dott. Bonapace is an Italy-based pharmaceutical service provider. Freund-Vector is a US-based pharmaceutical equipment and processing solution provider.
“The investments are a key component of AustinPx’s larger strategy to expand our oral dose development and manufacturing capabilities to better serve our clients’ increasing demand,” said Justin Keen, PhD, Senior VP of Operations. “The additions demonstrate our ongoing commitment to providing our clients with the best possible service and support."
In line with the company’s mission of providing science-driven formulation development, AustinPx has installed a PROCEPT modular 4M8-Trix for the development of spray-dried amorphous solid dispersions. The addition supplements AustinPx’s current portfolio of bioavailability enhancement technologies, including KinetiSol(registered trademark) Technology - the company’s proprietary fusion-based amorphous dispersion manufacturing platform.
“We are excited to add spray drying to our portfolio,” said Dave Miller, PhD, Chief Scientific Officer. “When combined with our existing formulation capabilities, the addition enables us to provide a comprehensive suite of bioavailability enhancement solutions to identify the optimal formulation pathway for poorly soluble compounds and address a greater number of our clients’ challenges.”
The expanded capabilities are now available for use. These additions are the first of several strategic investments planned for the company in the immediate future, as AustinPx continues to position itself as a leading CDMO in the pharmaceutical industry.